Clinician's Guide to Multiple Sclerosis
Treatment Approaches for MS Relapses
Written by Margaret Anne Rockwood | Last updated November 16th
Medically reviewed by Patricia K. Coyle, MD
Treatment of an acute multiple sclerosis (MS) relapse is intended to shorten the duration and severity of symptoms and accelerate functional recovery. It does not replace disease-modifying therapy (DMT), and corticosteroid treatment of an individual relapse has not been shown to change the long-term course of MS.
Before treatment, clinicians should determine whether symptoms represent a true relapse rather than infection, fever, metabolic disturbance, or another cause of transient worsening.
A pseudo-relapse typically reflects recrudescence of previous neurologic symptoms in response to a systemic stressor rather than new inflammatory disease activity. Urinary and respiratory infections, fever, and heat exposure should be considered. Treating a pseudo-relapse unnecessarily with high-dose corticosteroids can expose the patient to adverse effects while delaying treatment of the underlying trigger.
The neurologic examination should document the affected functional system and degree of disability. Magnetic resonance imaging can be useful when the diagnosis is uncertain or the presentation is atypical, although a clinically evident relapse does not always require imaging before treatment.
Corticosteroids
High-dose corticosteroids remain first-line treatment for functionally significant MS relapses.
High-dose methylprednisolone can be administered orally or intravenously. Evidence supports comparable efficacy of appropriately dosed oral and IV regimens, making route of administration largely dependent on severity, tolerability, access, and the need for inpatient monitoring.
Routine oral corticosteroid tapering after a short high-dose course generally does not improve recovery and usually is not necessary.
Common short-term adverse effects include insomnia, mood changes, dyspepsia, hyperglycemia, fluid retention, and metallic taste. Infection risk and glucose or blood pressure effects may require additional attention in susceptible patients. Severe psychiatric effects are uncommon but should be considered, particularly in patients with a relevant history.
Clinical improvement may continue within 1 to 2 weeks after starting methylprednisolone, while subsequent recovery can continue thereafter.
Mild relapses, particularly sensory attacks that have little effect on function or quality of life, may not require corticosteroids. The decision to treat should therefore reflect functional consequences as well as the presence of new neurologic symptoms.
ACTH
Repository corticotropin injection (adrenocorticotropic hormone or ACTH) is another option for acute relapse treatment, when high-dose corticosteroids are poorly tolerated or otherwise unsuitable. Adrenocorticotropic hormone stimulates endogenous corticosteroid production and may also exert direct anti-inflammatory and immunomodulatory effects through melanocortin receptors.
Adrenocorticotropic hormone is commercially available in the United States, but its use is less common than high-dose corticosteroids. Cost and insurance authorization can be important barriers, although more than one repository corticotropin product is now available and manufacturer assistance programs may reduce patient out-of-pocket costs.
Adrenocorticotropic hormone may also be considered in selected patients whose relapse responds inadequately to high-dose corticosteroids. That said, corticosteroids remain the usual first-line treatment, and for a severe, disabling steroid-refractory relapse, plasma exchange has an established role as a second-line therapy.
Plasma Exchange
Early treatment after recognition of steroid failure is recommended rather than allowing a severe deficit to persist for an extended period.
Therapeutic plasma exchange (PLEX) is an important rescue treatment for severe relapses that respond inadequately to corticosteroids, particularly disabling demyelinating attacks. Plasma is removed and replaced, reducing circulating antibodies and other inflammatory mediators.
Therapeutic plasma exchange is particularly relevant when a relapse produces major motor, visual, brainstem, or other disabling deficits and meaningful recovery has not followed high-dose corticosteroid treatment. Treatment commonly involves a series of exchanges rather than a single procedure.
In a 2024 retrospective study involving 127 severe MS relapses treated with PLEX, nearly three-quarters showed marked clinical improvement. Most patients had received corticosteroids first.
Additional Pharmacologic Approaches
Evidence for other rescue therapies is considerably weaker.
Intravenous immunoglobulin, which works to modulate an overactive immune response, may be considered in selected circumstances when standard approaches cannot be used or PLEX is unavailable.
Rare, severe, or fulminant inflammatory attacks may require individualized rescue strategies at an experienced MS center. In patients with persistent inflammatory activity despite corticosteroids and PLEX, reported approaches have included cyclophosphamide and, in selected circumstances, early use of high-efficacy MS therapy such as natalizumab and anti-CD20s.
Cyclophosphamide has the effect of broadly suppressing proliferating immune cells; rituximab depletes CD20-positive B cells; and natalizumab inhibits migration of inflammatory immune cells across the blood-brain barrier into the CNS.
Rehabilitation and Symptomatic Treatment
Relapse management does not end with immunotherapy. Physical, occupational, and other rehabilitation services may be useful when weakness, impaired gait, balance problems, or loss of independence persist during recovery. Symptomatic treatment for pain, spasticity, bladder dysfunction, and other manifestations may also improve function and quality of life while neurologic recovery occurs.
A relapse should also trigger a broader review of the patient’s disease. Recurrent attacks or unexpected MRI activity may indicate that the current DMT is not providing adequate disease control.
Sources
- Le Page E, Veillard D, Laplaud DA, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015;386(9997):974-981. doi:10.1016/S0140-6736(15)61137-0
- Marrodan M, Ysrraelit MC, Correale J. Therapeutic plasma exchange in corticosteroid-refractory multiple sclerosis relapses: mechanisms, efficacy, and integration into clinical practice. Biomedicines. 2025;13(10):2399. doi:10.3390/biomedicines13102399
- Mesaros S, Pekmezovic T, Martinovic V, et al. Beneficial therapeutic plasma exchange response in the treatment of severe relapses in patients with multiple sclerosis. Acta Neurol Belg. 2024;124(6):1885-1890. doi:10.1007/s13760-024-02606-w
- National Institute for Health and Care Excellence. Multiple sclerosis in adults: management. NICE guideline NG220. Published June 22, 2022. Updated June 3, 2026.
- Perumal JS, Caon C, Hreha S, et al., Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis. Eur J Neurol. 2008;15(7):677-680. doi:10.1111/j.1468-1331.2008.02146.x
- Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777-788. doi:10.1212/WNL.0000000000005347
- Ramo-Tello C, Blanco Y, Brieva L, et al. Recommendations for the diagnosis and treatment of multiple sclerosis relapses. J Pers Med. 2022;12(1):6. doi:10.3390/jpm12010006